BRITISH COLUMBIA, Canada, Feb. 4 /CNW/ -- InNexus Biotechnology Inc. (OTC
Bulletin Board: IXSBF; TSX Venture: IXS.V; http://www.ixsbio.com), a drug
development company commercializing the next generation of monoclonal
antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces
Jeff Morhet, Chairman and CEO, will be presenting at the 11th Annual BIO CEO &
Investor Conference on Tuesday, February 10th at 10:30-10:55 AM ET in the Park
Ballroom at the Waldorf-Astoria in New York City.
